Fracture incidence after 3 years of aromatase inhibitor therapy - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Annals of Oncology Année : 2014

Fracture incidence after 3 years of aromatase inhibitor therapy

, (1) , (2) , , (2) , , , (1) , (1) , (1) , , , (3) , (3) , (3)


BACKGROUND: The purpose of this study was to describe the fracture incidence and bone mineral density (BMD) evolution in a large cohort of post-menopausal women with breast cancer after 3 years of aromatase inhibitor (AI) therapy.

PATIENTS AND METHODS: A prospective, longitudinal study in real-life setting. Each woman had an extensive medical assessment, a biological evaluation, a BMD measurement, and systematic spinal X-rays at baseline and after 3 years of AI therapy. Women with osteoporosis at baseline (T-score < -2.5 and/or non-traumatic fracture history) were treated by oral weekly bisphosphonates.

RESULTS: Among 497 women (mean age 63.8 ± 9.6 years) included in this study, 389 had a bone evaluation both at baseline and after 3 years of AI therapy: 267 women (mean age 61.2 ± 8.6) with no osteoporosis at baseline and 122 women (mean age 67.2 ± 9.1) with osteoporosis at baseline justifying a weekly oral bisphosphonate treatment. Women without bisphosphonates had a significant decrease in spine BMD (-3.5%, P < 0.01), neck BMD (-2.0%, P < 0.01), and total hip BMD (-2.1%, P < 0.01) over the 3 years but only 15 of them (5.6%) presented an incident vertebral or non-vertebral fracture. In osteoporotic women treated with bisphosphonates, spine and hip BMD were maintained at 3 years but 12 of them (9.8%) had an incident fracture. These fractured women were significantly older (74.1 ± 9.8 versus 66.5 ± 8.8) but also presented BMD loss during treatment suggesting poor adherence to bisphosphonate treatment.

CONCLUSION: This real-life study confirmed that AIs induced moderate bone loss and low fracture incidence in post-menopausal women without initial osteoporosis. In women with baseline osteoporosis and AI therapy, oral bisphosphonates maintain BMD but were associated with a persistent fracture risk, particularly in older women.

Dates et versions

hal-03265961 , version 1 (21-06-2021)



Béatrice Bouvard, P. Soulié, Emmanuel Hoppé, Martine Georgin-Mege, Mathieu Royer, et al.. Fracture incidence after 3 years of aromatase inhibitor therapy. Annals of Oncology, 2014, 25 (4), pp.843-847. ⟨10.1093/annonc/mdu008⟩. ⟨hal-03265961⟩


10 Consultations
0 Téléchargements



Gmail Facebook Twitter LinkedIn More